Shi, Yuankai http://orcid.org/0000-0002-8685-6744
Chen, Jianhua
Zhang, Helong
Zhang, Zhihong
Zhang, Yiping
Wang, Zhehai
Zhang, Shucai
Zhao, Jian
Liu, Chunling
Wang, Xiuwen
Zhao, Yanqiu
Hu, Changlu
Yang, Lei
Hao, Xuezhi
Wang, Lin
Liu, Yunpeng
Yu, Yan
Zhao, Jun
Wang, Mengzhao
Zhang, Liangming
Sun, Sanyuan
Hu, Yanping
Gu, Kangsheng
Hang, Xiaosheng
Shan, Jinlu
Zhang, Yu
Tan, Bangxian
Yang, Weihua
Yang, Runxiang
Si, Meimei
Geng, Huaize
Li, Hui
Kang, Xiaoyan
Funding for this research was provided by:
Qilu Pharmaceutical Co., Ltd.
China National Major Project for New Drug Innovation (2017ZX09304015)
Article History
Received: 27 September 2022
Accepted: 13 January 2023
First Online: 24 February 2023
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice. The study protocol was approved by the ethics committees of each participating hospital. All patients provided written informed consent before participating in the study.
: Not applicable.
: Meimei Si, Hui Li, and Xiaoyan Kang are employees and Huaize Geng was a former employee of Qilu Pharmaceutical Co., Ltd., Jinan, China. All the other authors declare no competing interests.